Transgenic expression of single-chain anti-CTLA-4 Fv on β cells protects nonobese diabetic mice from autoimmune diabetes

Journal of Immunology

Volumn 183, Issue 4, 2009, Pages 2277-2285

  Shieh, Shing Jia ^a   Chou, Feng Cheng ^a   Yu, Pei Ning ^a   Lin, Wen Chi ^a   Chang, Deh Ming ^a   Roffler, Steve R ^b   Sytwu, Huey Kang ^a  

^a TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^b INSTITUTE OF BIOMEDICAL SCIENCES   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CD3 ANTIBODY; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; SINGLE CHAIN CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 FV ANTIBODY; UNCLASSIFIED DRUG; AUTOANTIBODY; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; CYTOTOXIC T-LYMPHOCYTE ANTIGEN 4; IMMUNOGLOBULIN FRAGMENT; IMMUNOGLOBULIN FV; LEUKOCYTE ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOIMMUNE DISEASE; CD4+ CD25+ T LYMPHOCYTE; CELL MATURATION; CELL TRANSPLANTATION; COCULTURE; DIABETES MELLITUS; DRUG INHIBITION; FEMALE; IMMUNE RESPONSE; IMPLANTATION; MOUSE; NONHUMAN; NONOBESE DIABETIC MOUSE; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SCID MOUSE; SPLEEN CELL; T LYMPHOCYTE; TH1 CELL; TH2 CELL; TRANSGENIC MOUSE; WILD TYPE; ANIMAL; ANTIBODY COMBINING SITE; BIOSYNTHESIS; CELL CULTURE; DISEASE MODEL; GENE TARGETING; GENETICS; IMMUNOGLOBULIN VARIABLE REGION; IMMUNOLOGY; INSULIN DEPENDENT DIABETES MELLITUS; MALE; METABOLISM; MOUSE MUTANT; PATHOLOGY; PHYSIOLOGY;

ANIMALS; ANTIGENS, CD; AUTOANTIBODIES; BINDING SITES, ANTIBODY; CELLS, CULTURED; COCULTURE TECHNIQUES; DIABETES MELLITUS, TYPE 1; DISEASE MODELS, ANIMAL; FEMALE; GENE TARGETING; IMMUNOGLOBULIN FRAGMENTS; IMMUNOGLOBULIN VARIABLE REGION; INSULIN-SECRETING CELLS; MALE; MICE; MICE, INBRED NOD; MICE, SCID; MICE, TRANSGENIC;

EID: 70149123492     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.0900679     Document Type: Article

References (45)

1. Bach, J.-F. 1994. Insulin-dependent diabetes mellitus as an autoimmune disease. Endocr. Rev. 15: 516-542.
2. Tisch, R., and H. McDevitt. 1996. Insulin-dependent diabetes mellitus. Cell 85: 291-297.
3. Wicker, L. S., J. A. Todd, and L. B. Peterson. 1995. Genetic control of autoimmune diabetes in the NOD mouse. Annu. Rev. Immunol. 13: 179-200.
4. Walunas, T. L., D. J. Lenschow, C. Y. Bakker, P. S. Linsley, G. J. Freeman, J. M. Green, C. B. Thompson, and J. A. Bluestone. 1994. CTLA-4 can function as a negative regulator of T cell activation. Immunity 1: 405-413.
5. Harding, F. A., J. G. McArthur, J. A. Gross, D. H. Raulet, and J. P. Allison. 1992. CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones. Nature 356: 607-609.
6. Krummel, M. F., and J. P. Allison. 1995. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J. Exp. Med. 182: 459-465.
7. Luhder, F., C. Chambers, J. P. Allison, C. Benoist, and D. Mathis. 2000. Pin-pointing when T cell costimulatory receptor CTLA-4 must be engaged to dampen diabetogenic T cells. Proc. Natl. Acad. Sci. USA 97: 12204-12209.
8. Tivol, E. A., F. Borriello, A. N. Schweitzer, W. P. Lynch, J. A. Bluestone, and A. H. Sharpe. 1995. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 3: 541-547.
9. Waterhouse, P., J. M. Penninger, E. Timms, A. Wakeham, A. Shahinian, K. P. Lee, C. B. Thompson, H. Griesser, and T. W. Mak. 1995. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science 270: 985-988.
10. Luhder, F., P. Hoglund, J. P. Allison, C. Benoist, and D. Mathis. 1998. Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) regulates the unfolding of autoimmune diabetes. J. Exp. Med. 187: 427-432. (Pubitemid 28080071)
11. Kristiansen, O. P., Z. M. Larsen, and F. Pociot. 2000. CTLA-4 in autoimmune diseases - a general susceptibility gene to autoimmunity? Genes Immun. 1: 170-184.
12. Chen, Z., J. Stockton, D. Mathis, and C. Benoist. 2006. Modeling CTLA4-linked autoimmunity with RNA interference in mice. Proc. Natl. Acad. Sci. USA 103: 16400-16405.
13. Griffin, M. D., D. K. Hong, P. O. Holman, K.-M. Lee, M. J. Whitters, S. M. O'Herrin, F. Fallarino, M. Collins, D. M. Segal, T. F. Gajewski, et al. 2000. Blockade of T cell activation using a surface-linked single-chain antibody to CTLA-4 (CD152). J. Immunol. 164: 4433-4442.
14. Hwang, K. W., W. B. Sweatt, I. E. Brown, C. Blank, T. F. Gajewski, J. A. Bluestone, and M.-L. Alegre. 2002. Cutting edge: targeted ligation of CTLA-4 in vivo by membrane-bound anti-CTLA-4 antibody prevents rejection of allogeneic cells. J. Immunol. 169: 633-637.
15. Fife, B. T., M. D. Griffin, A. K. Abbas, R. M. Locksley, and J. A. Bluestone. 2006. Inhibition of T cell activation and autoimmune diabetes using a B cell surface-linked CTLA-4 agonist. J. Clin. Invest. 116: 2252-2261.
16. H1 cells in autoimmune diabetes: evidence from a T1 and T2 doubly transgenic non-obese diabetic mouse model. J. Autoimmun. 25: 181-192.
17. Tuve, S., B.-M. Chen, Y. Liu, T.-L. Cheng, P. Toure, P. S. Sow, Q. Feng, N. Kiviat, R. Strauss, S. Ni, et al. 2007. Combination of tumor site-located CTL-associated antigen-4 blockade and systemic regulatory T-cell depletion induces tumor-destructive immune responses. Cancer Res. 67: 5929-5939.
18. Gilliland, L. K., N. A. Norris, H. Marquardt, T. T. Tsu, M. S. Hayden, M. G. Neubauer, D. E. Yelton, R. S. Mittler, and J. A. Ledbetter. 1996. Rapid and reliable cloning of antibody variable regions and generation of recombinant single chain antibody fragments. Tissue. Antigens 47: 1-20.
19. Griffin, M. D., P. O. Holman, Q. Tang, N. Ashourian, U. Korthauer, D. M. Kranz, and J. A. Bluestone. 2001. Development and applications of surface-linked single chain antibodies against T-cell antigens. J. Immunol. Methods 248: 77-90.
20. Sytwu, H.-K., W.-D. Lin, S. R. Roffler, J.-T. Hung, H.-S. Sung, C.-H. Wang, T.-L. Cheng, S.-C. Tsou, S.-C. Hsi, and K.-L. Shen. 2003. Anti-4-1BB-based immunotherapy for autoimmune diabetes: lessons from a transgenic non-obese diabetic (NOD) model. J. Autoimmun. 21: 247-254.
21. Sung, H.-H., J.-H. Juang, Y.-C. Lin, C.-H. Kuo, J.-T. Hung, A. Chen, D.-M. Chang, S.-Y. Chang, S.-L. Hsieh, and H.-K. Sytwu. 2004. Transgenic expression of decoy receptor 3 protects islets from spontaneous and chemical-induced autoimmune destruction in nonobese diabetic mice. J. Exp. Med. 199: 1143-1151.
22. Kurasawa, K., T. Koike, R. Matsumura, K. Takabayashi, H. Tomioka, I. Ito, and S. Yoshida. 1990. The immunosuppressant FK-506 prevents progression of diabetes in nonobese diabetic mice. Clin. Immunol. Immunopathol. 57: 274-279.
23. Kaufman, D. L., M. Clare-Salzler, J. Tian, T. Forsthuber, G. S. P. Ting, P. Robinson, M. A. Atkinson, E. E. Sercarz, A. J. Tobin, and P. V. Lehmann. 1993. Spontaneous loss of T-cell tolerance to glutamic acid decarboxylase in murine insulin-dependent diabetes. Nature 366: 69-72.
24. Juang, J.-H., C.-H. Kuo, and B. R.-S. Hsu. 2002. Effects of multiple site implantation on islet transplantation. Transplant. Proc. 34: 2698-2699.
25. Hotta, M., F. Tashiro, H. Ikegami, H. Niwa, T. Ogihara, J. Yodoi, and J.-i. Miyazaki. 1998. Pancreatic β cell-specific expression of thioredoxin, an antioxidative and antiapoptotic protein, prevents autoimmune and streptozotocin-induced diabetes. J. Exp. Med. 188: 1445-1451.
26. + T cells in the pathogenesis of organ-specific autoimmune diseases. Immunol. Today 16: 34-38.
27. Asano, M., M. Toda, N. Sakaguchi, and S. Sakaguchi. 1996. Autoimmune disease as a consequence of developmental abnormality of a T cell subpopulation. J. Exp. Med. 184: 387-396. (Pubitemid 26324092)
28. + T cells inhibit both the induction and effector function of autoreactive T cells and represent a unique lineage of immunoregulatory cells. J. Immunol. 160: 1212-1218.
29. + regulatory cells that control intestinal inflammation. J. Exp. Med. 192: 295-302.
30. + regulatory T cells constitutively expressing cytotoxic T lymphocyte- associated antigen 4. J. Exp. Med. 192: 303-310.
31. + regulatory T cells prevent graft rejection: CTLA-4- and IL-10-dependent immunoregulation of alloresponses. J. Immunol. 168: 1080-1086.
32. + regulatory T cell function. Eur. J. Immunol. 34: 2996-3005.
33. Kukreja, A., G. Cost, J. Marker, C. Zhang, Z. Sun, K. Lin-Su, S. Ten, M. Sanz, M. Exley, B. Wilson, et al. 2002. Multiple immuno-regulatory defects in type-1 diabetes. J. Clin. Invest. 109: 131-140.
34. Rabinovitch, A., O. Sorensen, W. L. Suarez-Pinzon, R. F. Power, R. V. Rajotte, and R. C. Bleackley. 1994. Analysis of cytokine mRNA expression in syngeneic islet grafts of NOD mice: interleukin 2 and interferon γ mRNA expression correlate with graft rejection and interleukin 10 with graft survival. Diabetologia 37: 833-837. (Pubitemid 24247855)
35. + T-cells in syngeneic islet grafts in NOD mice produce interferon-γ during β-cell destruction. Diabetes 45: 1350-1357.
36. Greenwald, R. J., V. A. Boussiotis, R. B. Lorsbach, A. K. Abbas, and A. H. Sharpe. 2001. CTLA-4 regulates induction of anergy in vivo. Immunity 14: 145-155.
37. Perez, V. L., L. Van Parijs, A. Biuckians, X. X. Zheng, T. B. Strom, and A. K. Abbas. 1997. Induction of peripheral T cell tolerance in vivo requires CTLA-4 engagement. Immunity 6: 411-417.
38. Chou, W.-C., K.-W. Liao, Y.-C. Lo, S. Y. Jiang, M. Y. Yeh, and S. R. Roffler. 1999. Expression of chimeric monomer and dimer proteins on the plasma membrane of mammalian cells. Biotechnol. Bioeng. 65: 160-169.
39. Liao, K.-W., Y.-C. Lo, and S. R. Roffler. 2000. Activation of lymphocytes by anti-CD3 single-chain antibody dimers expressed on the plasma membrane of tumor cells. Gene. Ther. 7: 339-347.
40. Grohmann, U., C. Orabona, F. Fallarino, C. Vacca, F. Calcinaro, A. Falorni, P. Candeloro, M. L. Belladonna, R. Bianchi, M. C. Fioretti, and P. Puccetti. 2002. CTLA-4-Ig regulates tryptophan catabolism in vivo. Nat. Immunol. 3: 1097-1101.
41. Augstein, P., G. Wachlin, S. Berg, J. Bahr, C. Salzsieder, B. Hehmke, P. Heinke, and E. Salzsieder. 2003. Surface and intracellular Fas expression associated with cytokine-induced apoptosis in rodent islet and insulinoma cells. J. Mol. Endocrinol. 30: 163-171.
42. Drage, M., P. Zaccone, J. M. Phillips, F. Nicoletti, J. Dawson, J. Andrew Bradley, and A. Cooke. 2002. Nondepleting anti-CD4 and soluble interleukin-1 receptor prevent autoimmune destruction of syngeneic islet grafts in diabetic NOD mice. Transplantation 74: 611-619.
43. Kagi, D., B. Odermatt, P. Seiler, R. M. Zinkernagel, T. W. Mak, and H. Hengartner. 1997. Reduced incidence and delayed onset of diabetes in perforin-deficient nonobese diabetic mice. J. Exp. Med. 186: 989-997.
44. Sandstrom, J., L. M. Jonsson, H. Edlund, D. Holmberg, and S. L. Marklund. 2002. Overexpression of extracellular-SOD in islets of nonobese diabetic mice and development of diabetes. Free. Radical Biol. Med. 33: 71-75.
45. Wang, C.-J., F.-C. Chou, C.-H. Chu, J.-C. Wu, S.-H. Lin, D.-M. Chang, and H.-K. Sytwu. 2008. Protective role of programmed death 1 ligand 1 (PD-L1) in nonobese diabetic mice: the paradox in transgenic models. Diabetes 57: 1861-1869.